Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ISRG's Cash-to-Debt is ranked higher than
98% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. ISRG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ISRG' s Cash-to-Debt Range Over the Past 10 Years
Min: 12.85  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
ISRG's Equity-to-Asset is ranked higher than
93% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ISRG: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
ISRG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.87 Max: 0.9
Current: 0.86
0.7
0.9
Interest Coverage No Debt
ISRG's Interest Coverage is ranked higher than
97% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. ISRG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ISRG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 26.61
Beneish M-Score: -2.66
WACC vs ROIC
7.31%
24.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 34.40
ISRG's Operating Margin % is ranked higher than
99% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. ISRG: 34.40 )
Ranked among companies with meaningful Operating Margin % only.
ISRG' s Operating Margin % Range Over the Past 10 Years
Min: 25.56  Med: 35.7 Max: 40.3
Current: 34.4
25.56
40.3
Net Margin % 27.99
ISRG's Net Margin % is ranked higher than
97% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. ISRG: 27.99 )
Ranked among companies with meaningful Net Margin % only.
ISRG' s Net Margin % Range Over the Past 10 Years
Min: 19.65  Med: 25.86 Max: 30.14
Current: 27.99
19.65
30.14
ROE % 15.35
ISRG's ROE % is ranked higher than
81% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ISRG: 15.35 )
Ranked among companies with meaningful ROE % only.
ISRG' s ROE % Range Over the Past 10 Years
Min: 12.17  Med: 18.96 Max: 21.36
Current: 15.35
12.17
21.36
ROA % 13.64
ISRG's ROA % is ranked higher than
91% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. ISRG: 13.64 )
Ranked among companies with meaningful ROA % only.
ISRG' s ROA % Range Over the Past 10 Years
Min: 10.59  Med: 16.51 Max: 18.44
Current: 13.64
10.59
18.44
ROC (Joel Greenblatt) % 159.97
ISRG's ROC (Joel Greenblatt) % is ranked higher than
97% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. ISRG: 159.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ISRG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 117.99  Med: 186.03 Max: 245.9
Current: 159.97
117.99
245.9
3-Year Revenue Growth Rate 6.80
ISRG's 3-Year Revenue Growth Rate is ranked higher than
60% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ISRG: 6.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ISRG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.65 Max: 57.1
Current: 6.8
0
57.1
3-Year EBITDA Growth Rate 4.80
ISRG's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. ISRG: 4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ISRG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: 29.4 Max: 318.7
Current: 4.8
-62.8
318.7
3-Year EPS without NRI Growth Rate 3.80
ISRG's 3-Year EPS without NRI Growth Rate is ranked higher than
53% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ISRG: 3.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ISRG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -61.5  Med: 20.9 Max: 76.8
Current: 3.8
-61.5
76.8
GuruFocus has detected 5 Warning Signs with Intuitive Surgical Inc $ISRG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ISRG's 10-Y Financials

Financials (Next Earnings Date: 2017-07-19 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ISRG Guru Trades in Q2 2016

RS Investment Management 10,680 sh (New)
Steven Cohen 13,500 sh (New)
Joel Greenblatt 13,254 sh (New)
Jeremy Grantham 91,193 sh (+20.63%)
Eaton Vance Worldwide Health Sciences Fund 110,000 sh (+30.95%)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Vanguard Health Care Fund 428,750 sh (-6.15%)
Manning & Napier Advisors, Inc 175,705 sh (-9.95%)
Robert Olstein 8,000 sh (-14.89%)
Pioneer Investments 3,708 sh (-45.42%)
Jim Simons 32,238 sh (-70.09%)
» More
Q3 2016

ISRG Guru Trades in Q3 2016

Ray Dalio 7,400 sh (New)
Lee Ainslie 1,750 sh (New)
Jim Simons 82,270 sh (+155.20%)
Pioneer Investments 3,708 sh (unchged)
Joel Greenblatt Sold Out
Manning & Napier Advisors, Inc 165,220 sh (-5.97%)
Robert Olstein 7,000 sh (-12.50%)
Jeremy Grantham 69,164 sh (-24.16%)
Vanguard Health Care Fund 243,169 sh (-43.28%)
Steven Cohen 3,900 sh (-71.11%)
Eaton Vance Worldwide Health Sciences Fund 56,174 sh (-48.93%)
» More
Q4 2016

ISRG Guru Trades in Q4 2016

John Hussman 10,000 sh (New)
Joel Greenblatt 2,698 sh (New)
John Paulson 10,100 sh (New)
Paul Tudor Jones 1,208 sh (New)
Ron Baron 11,216 sh (New)
Steven Cohen 12,200 sh (+212.82%)
Jim Simons 199,891 sh (+142.97%)
Robert Olstein 12,300 sh (+75.71%)
Pioneer Investments 5,081 sh (+37.03%)
Steven Cohen 20,000 sh (unchged)
Lee Ainslie 1,750 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 56,174 sh (unchged)
Manning & Napier Advisors, Inc 159,680 sh (-3.35%)
Jeremy Grantham 53,233 sh (-23.03%)
Vanguard Health Care Fund 186,869 sh (-23.15%)
Ray Dalio 1,700 sh (-77.03%)
» More
Q1 2017

ISRG Guru Trades in Q1 2017

Manning & Napier Advisors, Inc 51,049 sh (-68.03%)
» More
» Details

Insider Trades

Latest Guru Trades with ISRG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339113    SIC: 3841
Compare:NYSE:BSX, NYSE:ZBH, NYSE:STJ, NYSE:EW, OTCPK:SNNUF, NYSE:SYK, NAS:ALGN, OTCPK:SONVY, NYSE:TFX, NYSE:VAR, OTCPK:CNVVY, OTCPK:SDMHF, OTCPK:CHEOY, NAS:ABMD, OTCPK:WILYY, NAS:MASI, NAS:NUVA, OTCPK:FSPKF, OTCPK:EKTAY, OTCPK:GGNDF » details
Traded in other countries:IUI1.Germany, ISRG.Switzerland, 0R29.UK,
Headquarter Location:USA
Intuitive Surgical Inc designs, manufactures and markets da Vinci Surgical Systems and related instruments and accessories.

Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. Intuitive Surgical also provides the instrumentation, disposable accessories, and warranty services for the system. The firm has placed roughly 3,600 da Vinci systems in hospitals worldwide, with 2,400 installations in the U.S., 500-plus in Europe, and a growing number in emerging markets.

Guru Investment Theses on Intuitive Surgical Inc

Baron Opportunity Fund Comments on Intuitive Surgical - Feb 21, 2017

Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s robotic systems, implying substantial runway for growth.



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical - Feb 13, 2017

After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed using its robotic system, which together with annual service fees provides recurring revenue. Management has defined its current addressable market as four million procedures, but we believe Intuitive will continue to expand its addressable market by entering new procedure areas. The company has an exciting pipeline of new products, including a single port system that will enable new procedures and a robotic catheter system that will enable lung tissue biopsies to be taken minimally invasively. In the fourth quarter, the stock pulled back despite a strong fundamental outlook because investors became concerned that the repeal of the Affordable Care Act would cause Intuitive’s hospital customers to cut capital spending, which would negatively impact Intuitive’s system sales. We saw this pull-back as short-sighted and bought the stock. We think Intuitive can grow revenue and earnings at attractive rates over the long term.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Intuitive Surgical Inc

Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System
Intuitive Surgical Reports New Employee Option Grants for April 2017
Intuitive Surgical Reports New Employee Option Grants for March 2017

SUNNYVALE, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (NASDAQ:ISRG) today reported that equity awards, approved by the Compensation Committee of the Board of Directors, which consists entirely of Independent Directors, were made to 59 new employees. Pursuant to NASDAQ Marketplace Rule 5635(c)(4), the equity awards were granted under the Intuitive Surgical, Inc. 2009 Commencement Incentive Plan, which the Board of Directors of Intuitive Surgical, Inc. adopted for the granting of equity awards to new employees. In accordance with NASDAQ rules, these grants were made under an equity incentive plan without shareholder approval. NASDAQ rules require a public announcement of equity awards to be made under this type of plan.  59 employees were granted a combination of Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of 4,730 shares of the Company's common stock; 2,371 of the shares granted were Stock Options and 2,359 of the shares granted were RSUs. Both the RSUs and Stock Options vest over four years.  The Stock Options expire in 10 years assuming continued employment. No officers received any award under this plan. The exercise price for the Stock Options granted is $730.15 which was the closing price of Intuitive Surgical, Inc.'s common stock on the NASDAQ Global Market on March 7, 2017. The Company's policy is to issue RSUs and Stock Option grants to new employees, where equity makes sense, on the fifth business day of every calendar month.
About Intuitive Surgical, Inc. Intuitive Surgical, Inc. (NASDAQ:ISRG), headquartered in Sunnyvale, California, is the global technology leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets robotic technologies designed to improve clinical outcomes and help patients return more quickly to active and productive lives. The Company's mission is to extend the benefits of minimally invasive surgery to the broadest possible base of patients. Intuitive Surgical - Taking surgery beyond the limits of the human hand™. About the da Vinci® Surgical System The da Vinci® System is a breakthrough surgical platform designed to enable complex surgery using a minimally invasive approach. The da Vinci® System consists of an ergonomic surgeon console, a patient-side cart with four interactive robotic arms, a high-performance vision system and proprietary EndoWrist® instruments. Powered by state-of-the-art robotic and computer technology, the da Vinci® System is designed to scale, filter and seamlessly translate the surgeon's hand movements into more precise movements of the EndoWrist® instruments. The net result is an intuitive interface with breakthrough surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort, the da Vinci® Surgical System makes it possible for more surgeons to perform minimally invasive procedures involving complex dissection or reconstruction. This ultimately has the potential to raise the standard of care for complex surgeries, translating into numerous potential patient benefits, including less pain, a shorter recovery and quicker return to normal daily activities. Intuitive®, da Vinci®, da Vinci S®, da Vinci® Si™, InSite® and EndoWrist® are trademarks or registered trademarks of Intuitive Surgical, Inc. For more information, please visit the company's web site at www.intuitivesurgical.com.
CONTACT: Intuitive Surgical, Inc.
Investor Relations
408-523-2161

Read more...
Baron Opportunity Fund Comments on Intuitive Surgical Guru stock highlight
Intuitive Surgical (NASDAQ:ISRG) manufactures and markets the da Vinci Surgical System, a robotic surgical system consisting of a surgeon’s console, a patient-side cart, a high performance vision system and proprietary “wristed” instruments and surgical accessories. The da Vinci system seamlessly translates the surgeon’s natural hand movements on instrument controls at the console into corresponding micro-movements of instruments inserted into the patient through small puncture incisions or ports. The da Vinci provides the surgeon with the intuitive control, range of motion, fine tissue manipulation capability and 3-D vision characteristics of open surgery, while simultaneously allowing the surgeon to work through the small ports of minimally-invasive surgery. Patients treated with the da Vinci system benefit from improved clinical results, smaller incisions, fewer complications, less blood loss, less nerve damage, reduced pain and faster recovery compared with open surgery. The company is targeting four million annual surgical procedures worldwide and, we believe, this target is likely to increase over time. In 2016, roughly 750,000 procedures were performed using Intuitive’s Read more...
Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical Guru stock highlight
After a multi-year hiatus, we re-initiated an investment in Intuitive Surgical, Inc. (NASDAQ:ISRG) Intuitive sells the da Vinci robotic surgical system, which enables surgeons to perform minimally-invasive surgery in a number of different procedure categories. Minimally-invasive surgery benefits patients because they generally experience less pain and faster recovery after the procedure. Intuitive has held an effective monopoly on robotic-assisted surgery for many years. We believe the company has durable competitive advantages consisting of patents, technology, regulatory approvals, a worldwide installed base of systems, large salesforce, and balance sheet with over $4 billion in net cash. Although Intuitive is expected to face competitors in the future, we believe it will be difficult for competitors to displace the company and the company will maintain its leadership position. In 2016, roughly 750,000 procedures were performed worldwide using Intuitive’s robotic systems, an increase of 15% year-over-year. Intuitive generates revenue from instruments/accessories every time a procedure is performed Read more...
What Is Value? A discussion on intrinsic value
In a recent article one of the best writers on GuruFocus, Geoff Gannon, wrote the following: "The value investor in me – the stuff I learned from the books I read in my teens – rebels against the idea of paying a high (price-earnings) P/E for anything. That’s a mistake. It’s better to pay 30 times earnings for a company like Luxottica (NYSE:LUX) than 10 times earnings for a company like Weight Watchers (NYSE:WTW)." Read more...
Top Medical Companies Reach High Financial Strength A study of Altman Z-scores, Part 3: NYSE and Nasdaq companies have wider scores
Among all stocks trading on the New York Stock Exchange and Nasdaq, two medical companies, Intuitive Surgical Inc. (NASDAQ:ISRG) and Anika Therapeutics Inc. (NASDAQ:ANIK), have relatively strong Altman Z-scores. Read more...
Weekly CFO Sells Highlight Recent insider sells from company CFOs
According to GuruFocus Insider Data, the recent CFO sells were: Ross Stores Inc. (NASDAQ:ROST), Intuitive Surgical Inc. (NASDAQ:ISRG) and Facebook Inc. (NASDAQ:FB). Read more...
Weekly CFO Sells Highlight Insiders sell Honeywell, Intuitive Surgical, Michaels
According to GuruFocus Insider Data, the recent CFO sells were: Honeywell International Inc. (NYSE:HON), Intuitive Surgical Inc. (NASDAQ:ISRG) and The Michaels Companies Inc. (NASDAQ:MIK). Read more...

Ratios

vs
industry
vs
history
PE Ratio 42.00
ISRG's PE Ratio is ranked lower than
66% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 27.53 vs. ISRG: 42.00 )
Ranked among companies with meaningful PE Ratio only.
ISRG' s PE Ratio Range Over the Past 10 Years
Min: 17.77  Med: 37.37 Max: 107.2
Current: 42
17.77
107.2
Forward PE Ratio 35.21
ISRG's Forward PE Ratio is ranked lower than
77% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. ISRG: 35.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.00
ISRG's PE Ratio without NRI is ranked lower than
67% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. ISRG: 42.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
ISRG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.77  Med: 37.37 Max: 107.2
Current: 42
17.77
107.2
Price-to-Owner-Earnings 40.58
ISRG's Price-to-Owner-Earnings is ranked lower than
61% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 32.96 vs. ISRG: 40.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ISRG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.18  Med: 40.58 Max: 110.28
Current: 40.58
18.18
110.28
PB Ratio 7.79
ISRG's PB Ratio is ranked lower than
72% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. ISRG: 7.79 )
Ranked among companies with meaningful PB Ratio only.
ISRG' s PB Ratio Range Over the Past 10 Years
Min: 2.81  Med: 5.99 Max: 15.72
Current: 7.79
2.81
15.72
PS Ratio 11.72
ISRG's PS Ratio is ranked lower than
86% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ISRG: 11.72 )
Ranked among companies with meaningful PS Ratio only.
ISRG' s PS Ratio Range Over the Past 10 Years
Min: 4.16  Med: 9.74 Max: 24.28
Current: 11.72
4.16
24.28
Price-to-Free-Cash-Flow 34.07
ISRG's Price-to-Free-Cash-Flow is ranked lower than
54% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. ISRG: 34.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ISRG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 18.41  Med: 31.32 Max: 99.41
Current: 34.07
18.41
99.41
Price-to-Operating-Cash-Flow 30.91
ISRG's Price-to-Operating-Cash-Flow is ranked lower than
68% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. ISRG: 30.91 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ISRG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.34  Med: 27.26 Max: 84.53
Current: 30.91
11.34
84.53
EV-to-EBIT 28.17
ISRG's EV-to-EBIT is ranked lower than
57% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. ISRG: 28.17 )
Ranked among companies with meaningful EV-to-EBIT only.
ISRG' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 26.4 Max: 74.4
Current: 28.17
10.2
74.4
EV-to-EBITDA 25.71
ISRG's EV-to-EBITDA is ranked lower than
65% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. ISRG: 25.71 )
Ranked among companies with meaningful EV-to-EBITDA only.
ISRG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.5  Med: 24 Max: 60.8
Current: 25.71
9.5
60.8
PEG Ratio 10.69
ISRG's PEG Ratio is ranked lower than
82% of the 83 Companies
in the Global Medical Devices industry.

( Industry Median: 2.52 vs. ISRG: 10.69 )
Ranked among companies with meaningful PEG Ratio only.
ISRG' s PEG Ratio Range Over the Past 10 Years
Min: 0.15  Med: 1 Max: 18.34
Current: 10.69
0.15
18.34
Shiller PE Ratio 66.44
ISRG's Shiller PE Ratio is ranked lower than
62% of the 50 Companies
in the Global Medical Devices industry.

( Industry Median: 49.41 vs. ISRG: 66.44 )
Ranked among companies with meaningful Shiller PE Ratio only.
ISRG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 44.02  Med: 62.29 Max: 282.23
Current: 66.44
44.02
282.23
Current Ratio 3.88
ISRG's Current Ratio is ranked higher than
84% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. ISRG: 3.88 )
Ranked among companies with meaningful Current Ratio only.
ISRG' s Current Ratio Range Over the Past 10 Years
Min: 2.07  Med: 4.63 Max: 7.43
Current: 3.88
2.07
7.43
Quick Ratio 3.50
ISRG's Quick Ratio is ranked higher than
87% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. ISRG: 3.50 )
Ranked among companies with meaningful Quick Ratio only.
ISRG' s Quick Ratio Range Over the Past 10 Years
Min: 1.72  Med: 4.33 Max: 7.07
Current: 3.5
1.72
7.07
Days Inventory 79.89
ISRG's Days Inventory is ranked higher than
76% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. ISRG: 79.89 )
Ranked among companies with meaningful Days Inventory only.
ISRG' s Days Inventory Range Over the Past 10 Years
Min: 55.48  Med: 74.23 Max: 91.85
Current: 79.89
55.48
91.85
Days Sales Outstanding 54.13
ISRG's Days Sales Outstanding is ranked higher than
66% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. ISRG: 54.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
ISRG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.57  Med: 61.96 Max: 79.2
Current: 54.13
48.57
79.2
Days Payable 32.43
ISRG's Days Payable is ranked lower than
78% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. ISRG: 32.43 )
Ranked among companies with meaningful Days Payable only.
ISRG' s Days Payable Range Over the Past 10 Years
Min: 23.81  Med: 32.39 Max: 58.29
Current: 32.43
23.81
58.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.50
ISRG's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ISRG: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ISRG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -115.5  Med: -2.1 Max: 2.4
Current: -0.5
-115.5
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 40.94
ISRG's Price-to-Net-Cash is ranked higher than
52% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. ISRG: 40.94 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ISRG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.88  Med: 20.72 Max: 333.4
Current: 40.94
2.88
333.4
Price-to-Net-Current-Asset-Value 21.59
ISRG's Price-to-Net-Current-Asset-Value is ranked lower than
67% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. ISRG: 21.59 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ISRG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.21  Med: 12.24 Max: 28.5
Current: 21.59
2.21
28.5
Price-to-Tangible-Book 8.48
ISRG's Price-to-Tangible-Book is ranked lower than
61% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. ISRG: 8.48 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ISRG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.05  Med: 5.95 Max: 16.47
Current: 8.48
2.05
16.47
Price-to-Intrinsic-Value-Projected-FCF 2.77
ISRG's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
51% of the 129 Companies
in the Global Medical Devices industry.

( Industry Median: 2.23 vs. ISRG: 2.77 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ISRG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.5  Med: 2.54 Max: 14.57
Current: 2.77
1.5
14.57
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.48
ISRG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
68% of the 25 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. ISRG: 1.48 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.20
ISRG's Price-to-Median-PS-Value is ranked lower than
58% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. ISRG: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ISRG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 0.95 Max: 2.15
Current: 1.2
0.32
2.15
Price-to-Graham-Number 3.98
ISRG's Price-to-Graham-Number is ranked lower than
63% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. ISRG: 3.98 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ISRG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.8  Med: 3.52 Max: 8
Current: 3.98
1.8
8
Earnings Yield (Greenblatt) % 3.54
ISRG's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. ISRG: 3.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ISRG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.3  Med: 3.8 Max: 9.8
Current: 3.54
1.3
9.8
Forward Rate of Return (Yacktman) % 5.30
ISRG's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. ISRG: 5.30 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ISRG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.2  Med: 30 Max: 141.9
Current: 5.3
0.2
141.9

More Statistics

Revenue (TTM) (Mil) $2,784
EPS (TTM) $ 19.85
Beta0.85
Short Percentage of Float8.51%
52-Week Range $610.71 - 824.03
Shares Outstanding (Mil)36.84

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,975 3,316 3,663
EPS ($) 23.60 27.48 29.33
EPS without NRI ($) 23.60 27.48 29.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.84%
Dividends per Share ($)
» More Articles for ISRG

Headlines

Articles On GuruFocus.com
Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System Apr 26 2017 
Intuitive Surgical Reports New Employee Option Grants for April 2017 Apr 17 2017 
Intuitive Surgical Reports New Employee Option Grants for March 2017 Mar 13 2017 
Baron Opportunity Fund Comments on Intuitive Surgical Feb 21 2017 
Baron Funds' Fifth Avenue Growth Fund Comments on Intuitive Surgical Feb 13 2017 
John Hussman’s Top 3 New Holdings Feb 02 2017 
What Is Value? Nov 11 2016 
Classic Value Investing vs. Dynamic Value Investing Nov 02 2016 
Olstein All Cap Value Fund 2nd Quarter Letter to Shareholders Sep 01 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 

More From Other Websites
Intuitive Surgical Receives CE Mark for Latest da Vinci® Robotic-Assisted Surgical System Apr 26 2017
Dow Industrials Lead; Can These 4 Big Cap Stocks Smash S&P 500? Apr 25 2017
5 Stock Picks for April From Motley Fool Co-Founder David Gardner Apr 25 2017
ETFs with exposure to Intuitive Surgical, Inc. : April 24, 2017 Apr 24 2017
What Analysts Recommend for Intuitive Surgical after 1Q17 Results Apr 24 2017
What Drove Intuitive Surgical’s 1Q17 Growth? Apr 24 2017
Intuitive Surgical Reported Stellar 1Q17 Earnings Apr 24 2017
MasterCard, Intuitive Surgical and 2 More Could Rocket Higher This Spring--Here's Why … Apr 24 2017
[$$] Bank of America Beats Apr 21 2017
Intuitive Surgical, Inc. :ISRG-US: Earnings Analysis: Q1, 2017 By the Numbers : April 21, 2017 Apr 21 2017
Post Earnings Coverage as Intuitive Surgical's Quarterly Revenue Increased 13%; EPS Gained 15% Apr 21 2017
Intuitive Surgical: Q1 Solid, Procedures Likely to Slow Ddown Apr 21 2017
I Can't Believe Intuitive Surgical, Inc. Just Spent $2 Billion on Stock Buybacks Apr 20 2017
Here's How Intuitive Surgical Delivered a Blockbuster Quarter Apr 20 2017
What Happened in the Stock Market Today Apr 19 2017
Shares of this surgical robot maker just jumped to an all-time high on better-than-expected earnings Apr 19 2017
Robotic Surgeon Maker Launches To Record High On Strong Q1 Apr 19 2017
Techs Hold Lead Late; Morgan Stanley Results Fail To Stir Financials Apr 19 2017
Intuitive Surgical's Q1 Gives This Already Bullish Analyst 'Even Higher Confidence' Apr 19 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)